Hackensack Meridian Health
VC Fund
Edison, United States
Hackensack Meridian Health is a not-for-profit health care organization that offers medical services, research, and life care. They manage ambulatory care centers, surgery centers, home health services, long-term care and assisted living communities, ambulance services, lifesaving air medical transportation, fitness and wellness centers,rehabilitation centers, and urgent care centers.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Hackensack Meridian Health invests in
Stages Hackensack Meridian Health invests in
Countries Hackensack Meridian Health invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andrew Pecora
|
|||
Donna Snider
|
|||
John K. Lloyd
|
|||
Joseph Lemaire
|
|||
Kenneth Sable
|
Investment Focus
Industry
- Health Care 6 (100%)
- Biotechnology 3 (50%)
- Medical 2 (33%)
- Software 2 (33%)
- Information Technology 2 (33%)
Stage
- Series A 2 (33%)
- Series C 1 (17%)
- Private Equity 1 (17%)
- Corporate Round 1 (17%)
- Venture - Series Unknown 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Andrew Pecora
Senior Scientist, Institute for Biomedical Research
|
Senior Scientist, Institute for Biomedical Research | Total investments: 0 | Find email | |
|
Donna Snider
Chief Investment Officer
|
Chief Investment Officer | Total investments: 0 | Find email | |
|
John K. Lloyd
Co CEO
|
Co CEO | Total investments: 0 | Find email | |
|
Joseph Lemaire
President
|
President | Total investments: 0 | Find email | |
|
Kenneth Sable
President of Acute Care Hospital Division
|
President of Acute Care Hospital Division | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Canary Speech
|
Canary Speech is a technology company that uses AI-driven vocal digital biomarkers for conversational speech virtual health monitoring. The company's vocal biomarker technology enables voice to be used as a vital sign, ushering in a new era of machine learning in healthcare. Using only 20 seconds of conversational speech, its patented vocalbiomarker technology models acoustic and linguistic features and returns analysis. Canary detects stress, mood, and energy levels before traditional clinical screening and visible symptoms, allowing clinicians, payers, and patients to address conditions more proactively.Canary's technology reduces readmissions, prevents hospitalizations, and provides a head start on wellness for patients and providers. Its current research simulates respiratory conditions, dementia and Alzheimer's disease, and clinical deterioration, with broad practical implications for simulating other disease states. | $13M / Series A / Jun 11, 2024 | |
FluidForm Bio
|
FluidForm Bio™ is creating living human tissue for better treatment of disease. Our patented FRESH™ technology is a revolutionary platform designed to build tissue using cells, proteins, and nothing else. Through partnerships with top life science companies, our technology has been validated to produce the highest quality tissue in a variety ofapplications. We deliver human tissue that is indistinguishable from the real thing by integrating breakthrough innovations in 3D printing, computational and synthetic biology, AI, and advanced materials science. Our living tissue will offer therapies to countless patients who deserve better treatment options. FluidForm Bio™was founded in 2018 on the belief that the world needs transformational technologies led by creative and passionate experts that help people lead better lives. Headquartered in Waltham, MA. | Venture - Series Unknown / Jan 11, 2022 | |
Med-Metrix
|
Med-Metrix provides Performance Management and Revenue Cycle solutions to the healthcare industry. Designed specifically to improve clients' margins and productivity, their offerings leverage their proprietary FLOWtechnology platform ® of graphic-rich reporting and automated workflow coupled with advisory and outsource services as needed. | Private Equity / Sep 27, 2021 | |
EpiBone
|
EpiBone is a revolutionary bone reconstruction company that allows patients to “grow their own bone”. EpiBone’s pioneering technology utilizes a scan of the patient’s bone defect and the patient’s own stem cells to construct and cultivate a defect-specific autologous-like living bone graft. EpiBone is strategically positioned to provide a superiorbone graft that will provide exact defect repair, a simplified surgical procedure, improved bone formation and regeneration, and shorter recovery times, without the complications of foreign body implantation, to the over 900,000 patients who undergo bone-related surgeries each year. | Corporate Round / May 19, 2020 | |
Pillo Health
|
Pillo Health provides HIPAA compliant tools for caregivers and health organizations to deliver better care to loved ones and patients living at home. The company's care delivery platform is centered on an intelligent healthcare assistant called Pillo. In addition to managing medications, Pillo can provide patients at home with health andwellness information, can proactively deliver digital care plans into the home, and can connect the home to care teams via smart notifications and video calling. The company also offers an SDK for partner organizations to create their own unique skills for Pillo by leveraging the company's proprietary in home voice first device. | $11M / Series A / May 29, 2019 | |
COTA Healthcare
|
COTA was founded in 2011 by doctors, engineers, and data scientists to create clarity from fragmented and often-inaccessible real world data. By using proprietary technology, advanced analytics and deep expertise to organize complex data, COTA provides a comprehensive picture of cancer that can be used to advance care and research. | $40M / Series C / Feb 21, 2018 |
Co-Investors
Alvarez & Marsal Capital
1 deal together
A&M Capital Partners
1 deal together
BioAdvance
1 deal together
Boston Millennia Partners
1 deal together
Civilization Ventures
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Hackensack Meridian Health invest in?
Hackensack Meridian Health invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series C stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Hackensack Meridian Health?
Public channels for Hackensack Meridian Health include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Hackensack Meridian Health?
The team at Hackensack Meridian Health includes Andrew Pecora (Senior Scientist, Institute for Biomedical Research), Donna Snider (Chief Investment Officer) and John K. Lloyd (Co CEO), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
